Lung Adenocarcinoma Stage IIIB/IV
1 clinical trials · Condition
◉ Watch Lung Adenocarcinoma Stage IIIB/IV
| Record | Firm | Date |
|---|---|---|
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) (NCT02864992) | EMD Serono Research & Development Institute, Inc. | 2016-09-13 |
Track Lung Adenocarcinoma Stage IIIB/IV automatically
Every clearance here is in the API, with alerts when new ones post.